That's not going to detect relevant mutations for companies like LOXO.
Surveillance using liquid biopsies is generally going to be a nightmare because of the potential for over-diagnosis. The more sensitive the tests the worse the problem will be. But of course for diseases like ovarian or pancreatic cancer early diagnosis could be life-saving.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.